The passing of Abraham Hoffer
June 1, 2009 2:58 am Uncategorized, hallucinogen, humanMy pace of posting has slowed as I am deep in dissertation writing. So I have been remiss in failing to celebrate several good new articles, including a study of MDMA-cannabis interactions from Dumont and colleagues and an exciting article that considers one of my favorite topics: hallucinogens from a Bayesian perspective. However, my primary motivation for this entry is to note the death of psychedelic researcher Abraham Hoffer.
Hoffer was a psychiatrist and biochemist who collaborated with Humphrey Osmond in early studies of LSD and other psychedelics. Hoffer advanced a number of controversial claims, including the idea that LSD psychotherapy could help with alcoholism. Inspired by apparent similarities of LSD and delerium tremens and the observation that alcoholics who survived this dangerous withdrawal process sometimes improve, Hoffer and Osmond decided to test whether LSD might be useful as a treatment for alcoholism. As Mangini (1998) tells it:
In a search for a naturally occurring trace substance which could induce a schizophrenic-like reaction, Osmond and Abram Hoffer had studied the “schizogenic” properties of a group of materials, and had coined for them name “hallucinogens”: they included mescaline, lysergic acid diethylamide, harmine, ibogaine, and hashish (Hoffer, Osmond & Smythies 1954). Based upon speculation that the LSD experience could be akin to that of delirium tremens, a disorder involving visual and auditory hallucinatIons found in habitual and excessive users of alcoholic beverages, they began a series of studies of Iysergide in the treatment of alcoholism at Saskatchewan Hospital in Weyburn, where the first two alcoholics patients were treated in 1953 (Thomas 1977; Hoffer 1967).
Attempts to Simulate Delirium Tremens
The experience of delirium tremens is unpredictable, overwhelming and frightening. First described in 1813, it is sometimes referred to “the horrors,”, and may be accompanied by “rum fits” or seizures (Sutton 1813). It is the last in a continuum of alcohol withdrawal symptoms which may begin soon after the cessation of drinking as the blood level of alcohol begins to drop. It progresses erratically from agitation and autonomic hyperactivity, to mental confusion, disorientation, delusions and vivid hallucinations of colored snakes, dragons, and other fantastic objects. The patient may be amnestic for the experience (Adriani 1976). Delirium tremens occurs in about 4% to 5% of patients (Osmond 1969); in the early 1950s it was fatal in about 10% to 15% of patients; Advances in treatment have reduced mortality today to less than 5% (Yost 1996)
Hoffer and Osmond were familiar with the testimonies about “rapid abolition of ancient impulses and propensities (Osmond 1969: 218) collected by William James from the reformed drunkards of the Jerry McAuley Water Street Temperance Mission in 1902, and with James’ observation that the only radical remedy known to medicine “…for dispomania is religiomania” (James 1982). They were aware that ”a very remarkable experience” of some kind had been the cause of Bill W’s beginning to build Alcoholics Anonymous (AA) (Osmond 1969)
They knew that some kind of “hitting bottom” experience produced psychic states in which the subject recalled was at the heart of the Wesleyan Methodist sect’s success in converting alcoholics and helping them to stop drinkIng by catching them in the remorseful time after a drinking bout, scaring them thoroughly with the potential consequences of continued drinking, and then offering hope for improvement in a program of abstinence (Osmond 1969).
Because of these accounts of alcoholics who had experienced delirium tremens and sometimes were noted to “hit bottom” (an experience of surrender that is often consider -to be the key to beginning recovery from alcoholism, Hoffer and Osmond wondered if a similar experience, therapeutically induced, would help alcoholics stay sober (Hoffer 1967). They understood the LSD reaction to be similar in character to delirium tremens, but capable of being initiated at a time and placed that could be directed and controlled. Hoffer and Osmond speculated that one could inspire an alcoholic patient to “mend his ways” by inducing such an experience (Osmond 1969).
Hoffer and Osmond soon noted, however, that substances such as LSD and mescaline, which they had understood to produce hallucinations, could also produce “a particularly vivid and intense awareness of personality problems” which seemed to make the alcoholic more amenable to psychotherapy (Smith 1958). For many patients, this was also an “admonitory” experience, in which they were profoundly shocked and frightened by their vision of themselves and how alcohol was affecting them. Hoffer and Osmond abandoned the idea of provoking a simulacrum of the delirium tremens in favor of encouraging patients’ self examination of personality problems, and the development of insight into their “dismal present and appalling future”(Osmond 1969). They made no deliberate attempt to produce fear in their patients, since they had noted early in their investigations that making alcoholics afraid “often produces a desperate resolution to go on drinking” (Osmond 1969), and seemed to lead to severe anxiety and poor communication (Smith 1958).
In 1956 Humphry Osmond presented a paper at the New York Academy of Sciences conference entitled: “The Pharmacology of Psychotomimetic and Psychotherapeutic Drugs.” In this paper, which was “a review of the clinical effects of psychotomimetic agents,” Osmond described the major uses of this class of drugs. Some of these uses were the subject of ongoing research: the study of psychopathology through the production of “model psychoses,” the experiential training and education of psychiatrists and psychologists, and use as an adjunct to conventional psychotherapy. Two of the potential uses that he proposed were less well known: exploration of the normal mind under unusual conditions, and discoveries with social, philosophical, and religious implications made while using LSD and other drugs of this class (Osmond 1957). Osmond pointed out that to continue to consider these agents to be primarily “psychotomimetic” begged the question of their other potential uses. To prevent this, he proposed a new name for the class of drugs that would include their capacity to enrich the mind and enlarge the vision: psychedelic, a term coined from Greek roots indicating “manifesting the mind.” Research on the potential therapeutic benefits of psychedelic drugs in the treatment of the alcoholic continued for the next 12 years, producing innumerable areas of controversy.
They first tested the idea that LSD could help with alcoholism on two people who had been admitted to the Saskatchewan Mental Hospital for chronic alcoholism. Both received 200 ug LSD. Afterwards, one stopped drinking for at least six months (when the follow-up study ended) and the other continued to drink in the days after the treatment but stopped during the follow-up period. According to Erika Dyck’s excellent book, Psychedelic Psychiatry, Hoffer and Oswald and their colleagues went on to test more than 700 patients over the next ten years. Their methods and thinking became increasingly sophisticated. Again from Mangini (1998):
By 1957, when Hoffer and Osmond turned the Saskatchewan Hospital treatment program over to Colin Smith in order to continue their research on schizophrenia, the researchers had recognized that the environment, and especially the attitudes of the people’ around the LSD subject, influenced his experience profoundly. Reports of volunteers and patients also suggested that the drugs produced a “marked loosening of repression and greater facility in recognizing conflicts” (Chwelos et al. 1959). “Attitudes of love, faith and optimism” were desirable, as it appeared that the more intensely the patient experienced self-surrender and self-acceptance, the better the results (Chwelos et al, 1959: 585).
…
In 1958, Colin Smith (1959) wrote a follow-up article to his earlier report of the Saskatchewan Hospital pilot study entitled “Some Reflections on the Possible Therapeutic Effects of the Hallucinogens, with Special Reference to Alcohol.” It introduced some interesting topics that other researchers would later elaborate upon: he offered a thoughtful appraisal of some of the deficiencies in the existing research on LSD and mescaline and of their “putative therapeutic effects” (Smith 1959); and he attempted to address how the psychological effects of these drugs were understood in differing ways by different researchers.
The article outlined the technique then being used by the Saskatchewan Hospital group. Patients were first asked to freely give consent after a full discussion of the nature of the drug. After receiving their doses of LSD they were ….. encouraged to relax by listening to music and by examining paintings.” According to Smith, “It was hoped by this method to make the experience a thought-provoking one rather than a frightening one. At present, I avoid the use of suggestion during the experience, with one exception: I do suggest strongly to the patient that he discontinue drinking” (Smith 1958). Patients frequently were not asked to describe their experiences until the following day, and the overall tone produced was one of psychological safety and helpful friendliness (Smith 1959).
Treatment had been described in the original report of the pilot study as “LSD and mescaline used as adjuncts to treatment consisting of superficial psychotherapy supplemented by occupational and recreational therapy” (Smith 1958). In the follow-up article, Smith noted the well-known difficulty of estimating the effect of treatment in psychiatry. He recognized the way in which personal factors such as the style, training, and orientation of the therapist influence the psychological situation created in LSD therapy. In an attempt to standardize the “dose” of therapy, the Saskatchewan Hospital research group duplicated as exactly as possible the techniques that they had learned from Hubbard, and developed a treatment manual of individual and group procedures for the use of LSD (Blewett & Chwelos 1959). No objective measures of the therapeutic alliance of patient and therapist nor of primary patterns of the therapeutic relationship were used (as they would not be developed for almost 20 years).
Although they claimed excellent success rates, most of their clinical results went unpublished and what they did publish (e.g., Chwelos et al. 1959) failed to convince other researchers and the question of psychedelic therapy for alcoholism remains unanswered. (Mangini (1998) and Dyck (2006) provide useful discussions of the reasons for this.)
Hoffer had originally studied psychedelics because of an interest in schizophrenia and he continued to study schizophrenia after social concerns and government regulation made psychedelic research impractical. I think his work in this area is also very interesting. Hoffer had reported in 1955 that large doses of vitamin B3 (nicotinamide) could greatly decrease the effects of LSD. Based on this finding and thinking that an endogenous hallucinogen might explain schizoprenia, he went on to use B3 and other vitamins as a treatment for that disorder. Again, although Hoffer reported success, his treatment was not accepted by most other clinicians and researchers.
Schizophrenia is not my main area of expertise. It is a complicated syndrome and it may even be a collection of disorders with unrelated causes but similar signs and symptoms. Thus, I cannot evaluate the merits of Hoffer’s theories on schizophrenia. To my knowledge, not even the finding of B3 decreasing LSD effects has been convincingly replicated. (In later publications, Hoffer would cite two replications but I have not been able to obtain either and, from the abstract on erowid, one seems to be an unconvincing canine study. Anecdotal reports from people seem mixed and some have found the niacin-induced skin flush distressing.)
However, I suspect there is something interesting here that is worth pursuing. There have been reports for many years that people with schizophrenia (or family members with schizophrenia) have decreased sensitivity to the skin flushing effects of vitamin B3 (when taken as niacin) (e.g., Chang et al 2008) The term ‘flushing’ refers to vasodilation and a feeling of warmth that is believed to be the result of prostaglandin D2 (PGD2) release. PGD2 is made from arachidonic acid. Schizophrenics have sometimes been found to have reduced cell membrane levels of arachidonic acid and other polyunsaturated fatty acids. The decreased flushing from niacin may therefore represent an abnormality in arachidonic acid metabolism. Nutrition may be useful: Although they do not seem to be effective medications on their own, dietary polyunsaturated fatty acids may be beneficial when given in combination with psychotropic drugs and there are reasons to hypothesize that they might protect against eventual schizophrenia in fetuses and infants. Arachidonic acid is a very common messenger chemical in the brain and is a precursor to endocannabinoids. Because of this, it becomes easy for someone with access to pubmed to wave the hands and generate theories linking schizophrenia, cannabinoids, and serotonergic psychedelics. I don’t want to go too far afield and will simply note that there is much here that is worth further investigation.
I think it is no small achievement that Hoffer’s controversial findings and theories in this area are still relevant today, so many decades later. And, while some of the reductions in arachodonic acid and polyunsaturated fatty acids seen in schizophrenics may be the result of their diets, Hoffer’s point was partly that diet is important and nutrients can dramatically change health. His approach to treating schizophrenia was integrated and “based on the principles of respect, shelter, sound nutrition, appropriate medication and the administration of large doses of certain water-soluble vitamins”. So, yeah, he is remembered today for his controversial views. And I think it regrettable that his research did not ultimately have the convincing methods and publishable data to wow skeptics (including this one). Still, as I’ve encountered his thinking and writings, he got a lot of things right.

tero :
Date: August 25, 2009 @ 5:57 am
wow!
interesting studies. I am really keen on seeing some future results.
thanks for posting!